TY - JOUR
T1 - Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer
AU - Kutluk Cenik, Bercin
AU - Sun, Han
AU - Gerber, David E.
N1 - Funding Information:
Funding provided by the National Institutes of Health CTSA grant KL2RR024983 (North and Central Texas Clinical and Translational Science Initiative) (to D.E.G.) and National Cancer Institute Clinical Investigator Team Leadership Award (1P30 CA142543-01 supplement) (to D.E.G.).
PY - 2013/6
Y1 - 2013/6
N2 - Introduction: Certain chemotherapeutic agents commonly used for advanced non-small cell lung cancer (NSCLC) require minimum threshold renal function for administration. To determine how such requirements affect treatment options, we evaluated renal function patterns in this population. Methods: We performed a single-center retrospective analysis of patients treated for stage IV NSCLC from 2000 to 2007. Associations between patient characteristics, calculated creatinine clearance (CrCl), and clinical outcomes were determined using univariate and multivariate analyses, Cox proportional hazard models, and mixed model analysis. Results: 298 patients (3930 creatinine measurements) were included in the analysis. Patients had a median of 5 (interquartile range [IQR] 4-18) Cr measurements. Median baseline CrCl was 96. mL/min (IQR 74-123. mL/min); median nadir CrCl was 78. mL/min (IQR 56-100. mL/min). Renal function was associated with age (P<0.001), race (P=0.009), and gender (P=0.001). 23% of patients had a recorded CrCl. <. 60. mL/min (threshold for cisplatin), with median onset 83 days after diagnosis and median time to recover to ≥60. mL/min of 27 (IQR 3-85) days; 11% of patients had a recorded CrCl. <. 45. mL/min (threshold for pemetrexed), with median onset 122 days after diagnosis and median recovery time of 36 (IQR 3-73) days. For both thresholds, approximately 35% of patients had no documented recovery. Conclusions: In this cohort of patients treated for stage IV NSCLC, renal function falls below commonly used thresholds for cisplatin and for pemetrexed in fewer than a quarter of patients. However, these declines may preclude administration of these drugs for prolonged periods.
AB - Introduction: Certain chemotherapeutic agents commonly used for advanced non-small cell lung cancer (NSCLC) require minimum threshold renal function for administration. To determine how such requirements affect treatment options, we evaluated renal function patterns in this population. Methods: We performed a single-center retrospective analysis of patients treated for stage IV NSCLC from 2000 to 2007. Associations between patient characteristics, calculated creatinine clearance (CrCl), and clinical outcomes were determined using univariate and multivariate analyses, Cox proportional hazard models, and mixed model analysis. Results: 298 patients (3930 creatinine measurements) were included in the analysis. Patients had a median of 5 (interquartile range [IQR] 4-18) Cr measurements. Median baseline CrCl was 96. mL/min (IQR 74-123. mL/min); median nadir CrCl was 78. mL/min (IQR 56-100. mL/min). Renal function was associated with age (P<0.001), race (P=0.009), and gender (P=0.001). 23% of patients had a recorded CrCl. <. 60. mL/min (threshold for cisplatin), with median onset 83 days after diagnosis and median time to recover to ≥60. mL/min of 27 (IQR 3-85) days; 11% of patients had a recorded CrCl. <. 45. mL/min (threshold for pemetrexed), with median onset 122 days after diagnosis and median recovery time of 36 (IQR 3-73) days. For both thresholds, approximately 35% of patients had no documented recovery. Conclusions: In this cohort of patients treated for stage IV NSCLC, renal function falls below commonly used thresholds for cisplatin and for pemetrexed in fewer than a quarter of patients. However, these declines may preclude administration of these drugs for prolonged periods.
KW - Chemotherapy
KW - Cisplatin
KW - Creatinine clearance
KW - Non-small cell lung cancer
KW - Pemetrexed
KW - Renal function
UR - http://www.scopus.com/inward/record.url?scp=84877108626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877108626&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2013.02.011
DO - 10.1016/j.lungcan.2013.02.011
M3 - Article
C2 - 23499397
AN - SCOPUS:84877108626
SN - 0169-5002
VL - 80
SP - 326
EP - 332
JO - Lung Cancer
JF - Lung Cancer
IS - 3
ER -